Compare Amplify Cybersecurity ETF (HACK) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Novartis AG — how do they compare? Amplify Cybersecurity ETF trades at $108.21, while Novartis AG trades at $154.69 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while Amplify Cybersecurity ETF pays none, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| HACK | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $114.29 | $168.62 |
52-Week Low | $70.69 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $110.08, down 0.86% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX above 60). The ETF benefits from rising cybersecurity spending, which surpassed $300 billion in 2026 (24/7 Wall Street, 2026-07-03), and recently hit a 52-week high (Zacks Investment Research, 2026-05-26). Institutional interest is growing, with D.A. Davidson increasing its stake by 44.8% in Q1 2026 (Defense World, 2026-07-19).
Outlook remains positive due to structural demand for cybersecurity, but risks include sector volatility and reliance on tech spending. The ETF offers exposure to a high-growth theme, yet investors face concentration in tech and sensitivity to corporate budget cycles. Near-term resistance is at $111, with support at $110.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
